Abstract
We validated 2 multiplex real-time PCR (rtPCR) assays based on single nucleotide polymorphisms (SNPs) of the hemagglutinin-1 (HA1) gene of H3N8 equine influenza A virus (EIV) to determine clade affiliation of prototype and field isolates. Initial validation of the 2 multiplex rtPCR assays (SNP1 and SNP2) was performed using nucleic acid from 14 EIV Florida sublineage clade 1 and 2 prototype strains. We included in our study previously banked EIV rtPCR-positive nasal secretions from 341 horses collected across the United States in 2012–2017 to determine their clade affiliation. All 14 EIV prototype strains were identified correctly as either Florida sublineage clade 1 or clade 2 using the 2 SNP target positions. Of 341 EIV rtPCR-positive samples, 337 (98.8%) and 4 (1.2%) isolates were classified as belonging to clade 1 and 2 Florida sublineage EIV, respectively. All clade 1 Florida sublineage EIV strains were detected in domestic horses, three clade 2 Florida sublineage EIV strains originated from horses recently imported into the United States, and one clade 2 Florida sublineage EIV strain originated from a healthy horse recently vaccinated with a modified-live intranasal EIV vaccine containing the American lineage strain A/eq/Kentucky/1991. EIV Florida sublineage clade differentiation using a fast and reliable multiplex rtPCR platform will help monitor the introduction of clade 2 Florida sublineage EIV strains into North America via international transportation.
Contemporary equine influenza A virus (EIV; species Influenza A virus) strains circulating worldwide all belong to the H3N8 Florida sublineage (http://www.oie.int/our-scientific-expertise/specific-information-and-recommendations/equine-influenza). EIV surveillance data have shown that Florida sublineage viruses from both clade 1 and 2 circulate in Europe, whereas clade 1 viruses have been primarily reported from North America.3,6,7,10,11 Although only clade 1 is considered endemic in North America, clade 2 EIV has been detected in horses imported into the United States.1,12 Contemporary information on EIV clade affiliation in the United States is important not only from an epidemiologic standpoint but also to monitor and understand EIV outbreaks and update EIV vaccine strains in order to improve protection against clinical disease. In past years, clade affiliation of EIV strains has been monitored using conventional nucleic acid sequencing techniques, and more recently pyrosequencing, both of which are time- and labor-intensive.
Multiplex real-time PCR (rtPCR) assays for allelic discrimination have gained popularity in the equine infectious field to quickly and accurately discriminate between closely related viruses or genotypes of the same virus.2,4,5,16,17 Multiplex rtPCR assays are fast, highly sensitive and specific, and do not require post-amplification steps. Sanger dideoxynucleotide sequencing is still considered the method of choice for determining whole genome sequences and performing phylogenetic analysis. 13 From an epidemiologic standpoint, it is important to determine clade affiliation in real-time to monitor the introduction of clade 2 into North America via international transportation, monitor genetic drift of EIV, and monitor vaccine effectiveness. In an attempt to retain test accuracy, to further reduce turnaround time, and to monitor the occurrence of EIV clades in the United States, we established and validated a novel multiplex rtPCR assay targeting previously reported single nucleotide polymorphisms (SNPs) of the hemagglutinin-1 (HA1) gene of EIV.
Published sequences from GenBank (NCBI) of the HA1 gene of EIV clade 1 and 2 strains were subjected to BLAST analysis. These aligned sequences of clade 1 and 2 EIV strains were used to design primers and probes unique to each clade. Two SNPs along the HA1 gene (SNP1 and SNP2) were identified, and assays were developed to allow discrimination between clade 1 and 2 Florida sublineage EIV strains (Table 1). The fluorophore used for clade 1 was FAM and for clade 2 was VIC. All rtPCR assays were designed using the primer express software (Thermo Fisher Scientific, Foster City, CA) following the guidelines proposed for designing multiplex rtPCR assays. The optimum primer temperature was 58°C, and the temperature of the rtPCR probes was 10°C higher to encourage the probe to remain bound. Real-time PCR probes and primers were synthesized by Life Technologies (Grand Island, NY). The homology of the primers and rtPCR probes was confirmed using a BLAST search against the nonredundant database of GenBank.
Primers and probes used to validate 2 equine influenza A virus Florida sublineage clade-specific multiplex real-time PCR assays (SNP1 and SNP2) based on 2 SNPs of the HA1 gene.
Shaded nucleotides show the molecular differences between clade 1 and clade 2 equine influenza A virus. rtPCR = real-time PCR; SNP = single nucleotide polymorphism.
A total of 341 EIV rtPCR-positive samples (nasal secretions) collected in 2012–2017 (20 samples in 2012, 37 samples in 2013, 22 samples in 2014, 73 samples in 2015, 52 samples in 2016, and 137 samples in 2017) and kept frozen at −80°C were available for testing. Eighty-five EIV rtPCR-positive samples had been used previously to establish and validate a pyrosequencing assay able to differentiate between clade 1 and clade 2 Florida sublineage EIV strains. 1 Further, to assess the efficiency of multiplex rtPCR assays for the 2 EIV clades, analyses in triplicate were performed using Florida sublineage clade 1 (A/eq/Kentucky/1/2012, A/eq/New Hampshire/1/2013, A/eq/Ohio/1/2013, A/eq/Kentucky/1/2014, A/eq/Ohio/1/2014, A/eq/Kentucky/3/2015, A/eq/Minnesota/1/2015, A/eq/Illinois/1/2016, A/eq/New York/1/2016) and clade 2 (A/eq/Newmarket/5/2003, A/eq/Richmond/2007, A/eq/Shropshire/2010, A/eq/Devon/2011, A/eq/East Renfrewshire/2011), and one Eurasian lineage (A/eq/Aboyne/1/2005) EIV prototype strains.
All samples were processed for nucleic acid purification using an automated nucleic acid extraction system (CAS-1820 X-tractor Gene, Corbett Life Science, Mortlake, Australia) according to the manufacturer’s recommendations. The QuantiTect reverse transcription kit (Qiagen, Valencia, CA) was used for complementary DNA (cDNA) synthesis following the manufacturer’s directions with the following modifications. Ten microliters of RNA were digested with 1 μL of genomic DNA (gDNA) WipeOut buffer (Qiagen) by incubation at 42°C for 5 min and then briefly centrifuged. Genomic DNA contamination was tested by using 1 μL of digested RNA and running the rtPCR reference gene equine glyceraldehyde-3-phosphate dehydrogenase (eGAPDH). Then 0.5 μL of QuantiTect reverse transcriptase (Qiagen), 2 μL of QuantiTect RT buffer (Qiagen), 0.5 μL of RT primer mix (Qiagen), and 0.5 μL of 20 pmol random primers (Invitrogen, Carlsbad, CA) were added, brought up to a final volume of 20 μL, and incubated at 42°C for 40 min. The samples were inactivated at 95°C for 3 min, chilled, and 80 μL of water was added. Complementary DNA from nasal secretions was assayed for the presence of EIV using the 2 validated multiplex rtPCR assays.
The multiplex rtPCR primer–probe mixes were prepared by mixing 40 µL of the 100 pmol/µL forward primer, 40 µL of the 100 pmol/µL reverse primer, and 4 µL each of the two 100 pmol/µL probes in a final volume of 240 µL of water. The rtPCR reaction contained 0.42 μL of water, 0.58 µL of primer–probe mix (final concentration of 800 nM for each primer and 80 nM for the probe), 6 µL of commercial PCR master mix (Thermo Fisher Scientific), and 5 µL of the cDNA in a final volume of 12 µL. The samples were placed in a 384-well plate and amplified (7900HT Fast real-time PCR system, Thermo Fisher Scientific) using the manufacturer’s standard amplification conditions (2 min at 50°C, 10 min at 95°C, then 40 cycles of 15 s at 95°C and 60 s at 60°C). Fluorescent signals were collected during the annealing temperature, and the cycle threshold (Ct) was calculated and exported with a threshold of 0.1 and a baseline of 3–12. The Ct was defined as the cycle in which there was a significant increase in reporter signal, above the threshold. The 384-well plate was also analyzed using allelic discrimination with a 2-time point change in fluorescence. An X-Y graph was plotted with each allele on an axis. All contemporary EIV Florida sublineage clade 1 and 2 prototype strains were correctly identified using both multiplex rtPCR assays (Table 2). The Eurasian lineage prototype A/eq/Aboyne/1/2005 could not be definitively classified based on the 2 rtPCR multiplex assays. The multiplex rtPCR assay for SNP1 yielded a negative result; the multiplex rtPCR assay for SNP2 yielded a clade 2 result for A/eq/Aboyne/1/2005. Nucleotide sequence alignment of A/eq/Aboyne/1/2005 with the primers and probes of SNP1 and SNP2 multiplex rtPCR assays showed 2 nucleotide mismatches at position 281/282 and 524/525 of the HA1 gene, respectively (Fig. 1).
Validation results for 2 clade-specific multiplex rtPCR assays (SNP1 and SNP2) using selected EIV Florida sublineage clade 1 and 2 prototype strains.
EIV = equine influenza A virus; rtPCR = real-time PCR; SNP = single nucleotide polymorphism.
Nucleotide alignment of primers and probes for single nucleotide polymorphism (SNP)1 and SNP2 multiplex real-time PCR assays and partial nucleotide sequence of A/eq/Aboyne/1/2005 and A/eq/Kentucky/1991. Forward primer is highlighted in yellow, reverse primer in green, and probes are in blue. Nucleotide differences at positions 281/282 and 524/525 are in boldface.
Of the 341 EIV rtPCR-positive samples, 337 (98.8%) were classified as Florida sublineage clade 1 EIV strains; 4 (1.2%) were classified as Florida sublineage clade 2 EIV strains (Table 3). All EIV clade 1 Florida sublineage strains originated from domestic horses; 3 clade 2 Florida sublineage strains were from horses imported from Europe (2 horses from Germany and 1 horse from France). Two of the 3 horses originated from the same location in southern California and were diagnosed with equine influenza in March of 2012, whereas the third horse was located in Virginia at the time it was diagnosed with EIV (October 2014). One additional healthy horse, vaccinated with a modified-live virus (MLV) intranasal EIV vaccine (Flu Avert I.N., Merck Animal Health, Omaha, NE) 24 h prior to collection of nasal secretions tested positive by rtPCR for Florida sublineage clade 2 EIV. This horse was part of a clade 1 Florida sublineage EIV outbreak in December 2017 and sampled because of biosecurity protocols (i.e., healthy horses were sampled in order to monitor potential exposure to the outbreak EIV strain).
Equine influenza A virus Florida sublineage clade affiliation of 307 nasal secretions collected from 2012 to 2017.
Using a panel of contemporary isolated and characterized clade 1 and clade 2 Florida sublineage EIV strains, the 2 multiplex rtPCR assays yielded 3 outcomes: clade 1, clade 2, and discrepant results between SNP1 and SNP2 assays. Fourteen of 15 (93%) isolates were properly classified as clade 1 or clade 2 Florida sublineage EIV. Only one EIV Eurasian lineage isolate (A/eq/Aboyne/1/2005) gave equivocal results, prompting further sequence comparisons. The inability of the SNP1 multiplex rtPCR assay to detect A/eq/Aboyne/1/2005 was related to nucleotide mismatches at position 281/282 of the HA1 gene, preventing the binding of either of the 2 PCR probes. For SNP2, the single nucleotide mismatch at position 525 of the HA1 gene still allowed the annealing of 1 of the 2 PCR probes, and classified this strain as a clade 2 Florida sublineage EIV. Although the 2 multiplex rtPCR assays were initially designed to reliably classify clade affiliation, it appears that this technology will also be able to monitor EIV strains with discrepant results between the 2 SNP multiplex assays. The OIE expert surveillance panel on EIV reported that all viruses isolated and characterized in 2017 were from clades 1 and 2 of the Florida sublineage, and that Eurasian lineage and Kentucky and South America sublineage EIV isolates were presumed not to circulate any longer. However, one must keep in mind that global surveillance of equine influenza is not 100%, and other viruses not belonging to the Florida sublineage clade 1 or 2 may still be circulating undetected. Genetic characterization of contemporary EIV isolates is key to establishing vaccine strain recommendations, and it is not the goal of the multiplex SNP assays to replace in-depth genetic characterization of EIV strains. Discrepant results should always prompt the laboratory to further investigate the genetic makeup of the EIV strain through sequencing of the HA1 gene, thereby monitoring genetic drift.
Our results on clade affiliation for EIV strains collected from 341 horses with equine influenza showed that clade 1 has predominated in the United States during the last 6 y. This is in agreement with 2016 and 2018 studies,1,14 and also with the 2017 annual report of the OIE expert surveillance panel (http://www.oie.int/our-scientific-expertise/specific-information-and-recommendations/equine-influenza). A 2014 study has shown that the A/eq/Kentucky/91 cold-adapted intranasal EIV vaccine strain can be detected via rtPCR for up to 5 d in recently vaccinated horses. 9 Although the A/eq/Kentucky/91 strain is an American lineage strain, the nucleotide sequence at the level of both SNPs classified this strain as clade 2 Florida sublineage EIV. This means that the 2 assays able to detect Florida sublineage clade 2 EIV strains will also detect other American lineage viruses of the non-Florida sublineage. Although clade 2 Florida sublineage EIV strains do not appear to have yet become endemic in the United States, it is important to consider vaccination (especially in the face of recent use of a MLV intranasal vaccine) and travel history in any horse testing rtPCR-positive for Florida sublineage clade 2 EIV. Given that international transportation of horses has previously been shown to represent a major risk for influenza epidemics,8,15 it is important that resident horses be protected against the eventual introduction of contemporary EIV strains. The OIE expert surveillance panel on equine influenza vaccines supports the inclusion of both Florida sublineage clade 1 and clade 2 EIV isolates to help prevent failure of vaccine efficacy (http://www.oie.int/our-scientific-expertise/specific-information-and-recommendations/equine-influenza). Fortunately, various EIV vaccines containing both clade 1 and clade 2 Florida sublineage EIV strains are commercially available in the United States.
Footnotes
Acknowledgements
We thank the Animal Health Trust, Newmarket, United Kingdom, and the University of Kentucky, Lexington, KY, for sharing nucleic acid from selected EIV Florida sublineage clade 1 and clade 2 prototype strains. TM Chambers and S Reedy were supported by a project of the Kentucky Agricultural Experiment Station (KY014053).
Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
This study was supported by Boehringer Ingelheim Vetmedica through an Advancement in Equine Research Award.